Evolus, Inc.
EOLS · Price history
Price at last available close
$7.57
−$0.39 (-4.90%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Evolus, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines.
How they make money
Evolus operates a performance beauty company that generates revenue primarily through the sale of its aesthetic injectable products to medical aesthetic practices. The company utilizes a direct-to-customer commercial model supported by a digital platform and a loyalty program to drive product adoption, reorders, and customer retention within the aesthetic market.
Products & services
The company markets Jeuveau, a botulinum toxin type A injectable for the treatment of glabellar lines, and Evolysse, a line of dermal fillers.
Brands & revenue mix
Flagship botulinum toxin product.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Medical aesthetic practicesSource
Customer concentration
The company sells its products to a large number of individual medical aesthetic practices and does not rely on a single customer for a significant portion of its revenue as of the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
- Daewoong Pharmaceutical Co., Ltd. — The sole manufacturer and supplier of the company's flagship product, Jeuveau.Source
Business relationships & partnerships
- Daewoong Pharmaceutical Co., Ltd. — A South Korean pharmaceutical manufacturer that supplies Jeuveau to Evolus under a long-term distribution and supply agreement.Source
Competitors
- AbbVie Inc. — Competes in the aesthetic injectable market with its Botox product line.Source
- Galderma — Competes in the aesthetic injectable market with its Dysport and Restylane product lines.Source
- Revance Therapeutics, Inc. — Competes in the aesthetic injectable market with its Daxxify product.Source
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
24
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
41
Weak
Financial Strength
14
Business Quality / Moat
91
Management
33
Growth Quality
36
Risk / Durability
20
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
26
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
41/100
Building Historical Record
Model Score 41/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •CRITICAL: Going-concern warning
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for EOLS
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can EOLS maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can EOLS fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is EOLS's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for EOLS to reach sustainable profitability?
- •What future growth or profitability would be needed to justify EOLS's current valuation?
Essential Investment Snapshot
Wall Street Score
24
Opportunity Score
26
Market Cap
$500.6M
P/E Ratio
-15.4
EPS
$-0.52
52-Week High
$9.31
52-Week Low
$3.86
Beta
1.43
Analyst Target
$17.00
Shares Outstanding
64.5M
Total Revenue
$316.5M
Total Debt
$164.8M
Dividend
No current dividend
Liquidation Value / Share
$-0.48
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for EOLS
Detected from reported data — verify before acting.CRITICAL: Going-concern warning
Reported financials show negative stockholders' equity, a net loss, and negative operating cash flow — a combination that raises substantial doubt about the company's ability to continue as a going concern. Wall Street Score is subject to a severe hard cap.
Elevated debt risk
Negative shareholder equity • Interest coverage is below 2x • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on EOLS.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Digitally enabled commercial platform.
- +High customer reorder rates.
Potential downside factors
- −Debt risk (elevated): Negative shareholder equity.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
- −Reliance on a single supplier (Daewoong) for Jeuveau.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
24
Sep 21, 2026
Change
Unchanged
Current Score
24
Oct 1, 2026
Category Changes
EOLS score was unchanged.
Projected Score
Projected Score
21
Projected Change
-3.4 points
Preliminary comparable-period financial changes suggest decline of approximately 3.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$7.58
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $316.5M | $297.2M | $266.3M | $202.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $106.8M | $104.4M | $84.0M | $61.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $209.7M | $192.8M | $182.3M | $140.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $9.7M | $9.6M | $9.2M | $15.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $216.5M | $220.8M | $198.0M | $164.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $232.9M | $230.4M | $216.7M | $189.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$10.2M | -$22.5M | -$25.0M | -$41.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$23.2M | -$37.6M | -$34.4M | -$49.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $16.2M | $19.7M | $18.7M | $13.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$33.7M | -$51.0M | -$49.8M | -$61.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $654K | $677K | $664K | $176K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$34.3M | -$51.6M | -$50.4M | -$61.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.52 | $-0.80 | $-0.81 | $-1.08 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 65.93M | 64.47M | 62.02M | 56.92M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 65.93M | 64.47M | 62.02M | 56.92M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$84.1M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.12
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+6.4%
Cash Change
-26.8%
Margin Change
+15.1 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
What Weakened
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, net income margin. Pressure indicators included EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 21.2%. EPS declined 55.6%. Cash declined 26.8%. Total debt increased 6.4%. Net income margin improved by 15.1 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - Specialty & GenericNews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
Rumor Mill · EOLS
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial